Recently, Viva Biotech's portfolio companies have new updates: AceLink and Genhouse Bio made solid progress in R&D; Mediar entered into a major collaboration.
AceLink Therapeutics Presents Interim Results from a Phase 2 Trial of the GCS Inhibitor AL01211 in Treatment-Naïve, Classic Male Fabry Disease Patients at the WORLD Symposium 2025
San Francisco & Shanghai – February 7, 2025 – AceLink Therapeutics, Inc. (“AceLink”), invested and incubated by Viva BioInnovator (VBI), a clinical-stage biotech company developing next-generation oral substrate reduction therapies (SRTs), presented interim data from its ongoing Phase 2 clinical study of AL01211 in treatment-naïve, classic male Fabry disease patients. These findings were highlighted in a late-breaking oral platform presentation at the 2025 WORLD Symposium in San Diego, California. Interim results indicate that AL01211 is generally safe and well tolerated in classic male Fabry patients. Treatment with 30 mg once daily reduced GL3 levels by 50%, while a higher daily dose of 60 mg resulted in a faster and greater reduction of GL3 substrate levels.
Genhouse Bio's New Generation PRMT5 Inhibitor GH56 Clinical Trial Application Approved by NMPA
Suzhou, China – January 16, 2025 – Genhouse Bio, invested and incubated by VBI, a biotech company focusing on development of next-generation anti-cancer therapeutics, announced that its clinical trial application for the next generation PRMT5 inhibitor GH56, a Class 1 new drug, has been approved by NMPA. Additionally, on January 24, the clinical trial application for GH56 in the United States was approved by the FDA.
Mediar Therapeutics Enters into Global Licensing Agreement with Lilly to Advance First-in-Class WISP1 Antibody for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Boston – January 10, 2025 – Mediar Therapeutics, Inc. (“Mediar”), invested by VBI, a clinical stage biotechnology company advancing a portfolio of first-in-class therapies designed to halt fibrosis progression, announced a global licensing agreement with Eli Lilly and Company to advance MTX-463 into a Phase 2 clinical trial for idiopathic pulmonary fibrosis (IPF). Under the terms of the agreement Mediar will receive a combined $99 million, which is inclusive of an upfront payment and near-term milestones. Mediar may receive up to an additional $687 million in potential downstream development and commercialization milestones. Additionally, Mediar is eligible to receive high-single to low-double digit royalty payments and net sales milestones based on potential future product sales.
About AceLink Therapeutics, Inc.
Founded in 2018, AceLink Therapeutics is an innovative biopharma startup focusing on developing safe and effective medicines to address genetic diseases with high unmet needs. The company’s initial focus is to develop novel therapeutics for Fabry disease. For more information, please visit www.acelinktherapeutics.com.
About Genhouse Bio
Genhouse Bio is a clinical-stage biotech company focusing on the development of global next-generation anti-cancer therapeutics. The senior management team of Genhouse has multiple years of experience in new drug development, clinical research and corporate management. Genhouse has a clear focus on original innovation and overcoming those “undruggable” targets. Genhouse has established intergrated in-house drug development platforms. With these platforms, Genhouse has started to build a highly innovative anti-cancer pipeline and out-licensed the ex-China rights of its SHP2 inhibitor GH21 to HUYABIO , an international biotech company. Genhouse will continue to advance more innovative pipeline programs into global development.
About Mediar Therapeutics
Mediar Therapeutics is pioneering a new approach to fibrosis treatment that aims to halt the disease at a different source – the myofibroblast, the key pathogenic cell in fibrosis that drives scarring, disease progression, and ultimately organ failure. Mediar was founded based on a deep understanding of the complex science underlying fibrosis progression. By combining novel targets with reliable, easily detectable blood biomarkers and familiar modalities, Mediar's goal is to bring forward novel anti-fibrotic therapies that potentially have a precision medicine approach.
Copyright © Viva Biotech All Rights Reserved. 沪ICP备19036061号